Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance after beating third-quarter profit forecasts, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,